Navigation Links
Quark Pharmaceuticals to Present at American Society for Pharmacology and Experimental Therapeutics Annual Meeting
Date:4/20/2009

P covering synthetic siRNAs and validating partnerships with companies such as Pfizer."

Dr. Thompson has been a leader in siRNA development for several years. Prior to joining Quark, he was Director of Research and Development at Genta, and previously was Director of Biology Research at Ribozyme Pharmaceuticals, which was acquired by Merck after changing its name to Sirna Therapeutics.

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel RNAi-based therapeutics. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability for non-invasive delivery of siRNA to other target tissues including the eye, ear, lung, spinal cord and brain.

PF-4523655 (RTP801i-14), currently in Phase II clinical trials, is a synthetic, chemically modified siRNA designed to inhibit the expression of the gene RTP801 discovered by Quark through the gene discovery platform BiFAR. PF-4523655 is licensed to Pfizer. In addition, Quark's current clinical pipeline includes QPI-1002, the first systemically administered siRNA drug in human clinical trials, developed by Quark for the prevention of acute kidney injury (AKI) following major cardiac surgery and of delayed graft function in kidney transplantation. For the structure of these products Quark has licenses from Silence Therapeutics and from Alnylam Pharmaceuticals.

QPI-1007, a siRNA that utilizes a proprietary structure developed by Quark, is being evaluated in advanced IND-enabling preclinical studies as a neuroprotective agent for eye diseases. In addition, Quark has a broad pipeline of siRNA drug candidates based on novel
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008
2. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
3. Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference
4. Mpex Pharmaceuticals Names Mark Wiggins Chief Business Officer
5. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
6. Sunesis Pharmaceuticals Receives NASDAQ Notification
7. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
8. XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel
9. Accera, Inc. Launches Neuera Pharmaceuticals, Inc.
10. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
11. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... 16, 2013 Oven Industries, Inc. has ... and temperature sensors since 1964. Expertly designed, ... industrial control system applications. As one of ... a generic, control loop feedback system, which helps minimize ... to adjust a systematic process, using a control element, ...
(Date:5/16/2013)... Cambridge Healthtech Institute will host its fifth annual ... Renaissance Waterfront Hotel in Boston, MA. The ten ... the current strategies and innovations for optimizing bioprocesses while ... the field will reveal how their work has resulted ... and efficiency. , “In this age of rapid innovation, ...
(Date:5/16/2013)... 16, 2013  The registration deadline has been extended ... (ABFO) 2013 National Conference, the premier conference for bioscience ... at the Hilton San Diego Bayfront. ... conference and want to make sure as many people ... Brandi Roberts , Chief Financial Officer of ...
(Date:5/16/2013)... On average, developing a new drug takes ... Despite this investment, less than 10% of drugs make ... clinical trial design optimally structured to balance time, cost ... Frederic Sax, Global Head of the Center for Drug ... information and technology in upfront clinical trial planning and ...
Breaking Biology Technology:New PID Temperature Controllers Announced by Oven Industries Inc. 2The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 3Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 4Optimizing Clinical Trials Outcomes through Computer Assisted Design, New Life Science Webinar Hosted by Xtalks 2
... across Wisconsin are learning new ways to produce ... soybeans, solar collectors, corn stover, wind farms, grease, ... ,State businesses, architects, and builders are national leaders ... energy and money. , ,Wisconsin policymakers and utility ...
... , one the nation's major credit-card processing companies, agreed to ... Kohlberg Kravis Roberts & Co. , for $29 billion. The ... among the 10 largest buyouts ever and signals the continued ... debt and eager institutional investors like pension funds. , ,What ...
... Monica, Calif. - The United States Patent and ... patents held by the Wisconsin Alumni Research Foundation , ... as the legal process continues to unfold. , ,Every WARF ... claim to stem cells, themselves, has been rejected by examiners ...
Cached Biology Technology:Wisconsin can offer what a federal energy research lab needs 2Wisconsin can offer what a federal energy research lab needs 3Wisconsin can offer what a federal energy research lab needs 4Of private equity, research, and drug development 2Of private equity, research, and drug development 3Of private equity, research, and drug development 4Of private equity, research, and drug development 5Patent office upholds challenge to WARF stem cell patents 2Patent office upholds challenge to WARF stem cell patents 3
(Date:5/16/2013)... million years old give unprecedented insight into the ... the most species-rich groups among the modern bony ... Reichenbacher from the Division of Paleontology and Geobiology ... at Ludwig-Maximilians-Universitaet (LMU) in Munich / Germany have ... they assign to the group of bony fishes ...
(Date:5/16/2013)... Top neuroscientists from Canada and around the world ... Annual Canadian Neuroscience Meeting will showcase the latest ... system and reveal clues to understanding the disorders ... neuroscience research, and this meeting will showcase the ... the world," says Sam David, President of the ...
(Date:5/16/2013)... May 16, 2013 Reportlinker.com announces ... available in its catalogue: ... 2018 http://www.reportlinker.com/p01181929/Global-Biometric-Systems-Market-Forecast--Opportunities-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Security_Systems ... security practises such as photographs, passwords and ... biometric technologies in last few years. Security ...
Breaking Biology News(10 mins):Paleontology: The eloquence of the otoliths 2Paleontology: The eloquence of the otoliths 37th Annual Canadian Neuroscience Meeting, Toronto, May 20-24, 2013 2Global Biometric Systems Market Forecast & Opportunities, 2018 2Global Biometric Systems Market Forecast & Opportunities, 2018 3Global Biometric Systems Market Forecast & Opportunities, 2018 4Global Biometric Systems Market Forecast & Opportunities, 2018 5Global Biometric Systems Market Forecast & Opportunities, 2018 6Global Biometric Systems Market Forecast & Opportunities, 2018 7
... RIVERSIDE, Calif. Avocado, a significant fruit crop ... world, is threatened by Phytophthora root rot (PRR), a ... many areas in Latin America and crippled production in ... disease is estimated to cost avocado growers approximately $30-40 ...
... can boost conservation in China,s valued panda preserves, but ... the humans who live there, a unique long-term study ... tourism are people who already have resources. The truly ... business, according to the paper, "Drivers and Socioeconomic Impacts ...
... press release is available in German . ... crops has substantially increased around the world. As a team ... the Technical University of Dresden and the University of Freiburg ... and temporal trends of global pollination benefit" in the open-access ...
Cached Biology News:New avocado rootstocks are high-performing and disease-tolerant 2New avocado rootstocks are high-performing and disease-tolerant 3Can nature's beauty lift citizens from poverty? 2Can nature's beauty lift citizens from poverty? 3Global prices of pollination-dependent products such as coffee could rise in the long term 2Global prices of pollination-dependent products such as coffee could rise in the long term 3
Mouse monoclonal [3576] to Yellow Fever Virus ( Abpromise for all tested applications). Antigen: Tissue / cell preparation...
... Level 2 Detection System combines the ... bonding principle and Signets unique formulation ... specificity and reliablility. Signet reagents will ... manual and automated protocols. ,Signets ...
6X Loading Buffer is intended for gel electrophoresis of DNA fragments or PCR products....
Ideally suited for resolving DNA and RNA 10-1000 bases especially PCR products ranging from 100-1000 bp. Gelling temp. (4%) 27C Melting temperature 65C. EEO: 0.10 Rnase/Dnase: none detected...
Biology Products: